Literature DB >> 11578772

CD40 signaling and Alzheimer's disease pathogenesis.

T Town1, J Tan, M Mullan.   

Abstract

The interaction between CD40 and its cognate ligand, CD40 ligand, is a primary regulator of the peripheral immune response, including modulation of T lymphocyte activation, B lymphocyte differentiation and antibody secretion, and innate immune cell activation, maturation, and survival. Recently, we and others have identified CD40 expression on a variety of CNS cells, including endothelial cells, smooth muscle cells, astroglia and microglia, and have found that, on many of these cells, CD40 expression is enhanced by pro-inflammatory stimuli. Importantly, the CD40-CD40 ligand interaction on microglia triggers a series of intracellular signaling events that are discussed, beginning with Src-family kinase activation and culminating in microglial activation as evidenced by tumor necrosis factor-alpha secretion. Based on the involvement of microglial activation and brain inflammation in Alzheimer's disease pathogenesis, we have investigated co-stimulation of microglia, smooth muscle, and endothelial cells with CD40 ligand in the presence of low doses of freshly solubilized amyloid-beta peptides. Data reviewed herein show that CD40 ligand and amyloid-beta act synergistically to promote pro-inflammatory responses by these cells, including secretion of interleukin-1 beta by endothelial cells and tumor necrosis factor-alpha by microglia. As these cytokines have been implicated in neuronal injury, a comprehensive model of pro-inflammatory CD40 ligand and amyloid-beta initiated Alzheimer's disease pathogenesis (mediated by multiple CNS cells) is proposed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578772     DOI: 10.1016/s0197-0186(01)00044-4

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  17 in total

Review 1.  T-cells in Alzheimer's disease.

Authors:  Terrence Town; Jun Tan; Richard A Flavell; Mike Mullan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

2.  Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice.

Authors:  William V Nikolic; Huayan Hou; Terrence Town; Yuyan Zhu; Brian Giunta; Cyndy D Sanberg; Jin Zeng; Deyan Luo; Jared Ehrhart; Takashi Mori; Paul R Sanberg; Jun Tan
Journal:  Stem Cells Dev       Date:  2008-06       Impact factor: 3.272

Review 3.  Impact of the CD40-CD40L dyad in Alzheimer's disease.

Authors:  Brian Giunta; Kavon Rezai-Zadeh; Jun Tan
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

4.  Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-β-associated neuropathology in Alzheimer mice.

Authors:  Donna Darlington; Juan Deng; Brian Giunta; Huayan Hou; Cyndy D Sanberg; Nicole Kuzmin-Nichols; Hua-Dong Zhou; Takashi Mori; Jared Ehrhart; Paul R Sanberg; Jun Tan
Journal:  Stem Cells Dev       Date:  2012-09-05       Impact factor: 3.272

5.  Dyad of CD40/CD40 ligand fosters neuroinflammation at the blood-brain barrier and is regulated via JNK signaling: implications for HIV-1 encephalitis.

Authors:  Servio H Ramirez; Shongshan Fan; Holly Dykstra; Nancy Reichenbach; Luis Del Valle; Raghava Potula; Richard P Phipps; Sanjay B Maggirwar; Yuri Persidsky
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

6.  SOLUBLE CD40 LIGAND IN DEMENTIA.

Authors:  B Giunta; K P Figueroa; T Town; J Tan
Journal:  Drugs Future       Date:  2009-04-01       Impact factor: 0.148

Review 7.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

Review 8.  Alternative Abeta immunotherapy approaches for Alzheimer's disease.

Authors:  Terrence Town
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

9.  CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation.

Authors:  D Obregon; H Hou; Y Bai; W V Nikolic; T Mori; Deyan Luo; J Zeng; J Ehrhart; F Fernandez; D Morgan; B Giunta; T Town; J Tan
Journal:  Neurobiol Dis       Date:  2007-10-16       Impact factor: 5.996

10.  The microglial "activation" continuum: from innate to adaptive responses.

Authors:  Terrence Town; Veljko Nikolic; Jun Tan
Journal:  J Neuroinflammation       Date:  2005-10-31       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.